Published in Int J Mol Sci on June 02, 2015
Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med (2004) 14.00
Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest (2003) 13.72
Pre-eclampsia. Lancet (2010) 7.46
Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med (2006) 7.06
The global impact of pre-eclampsia and eclampsia. Semin Perinatol (2009) 5.50
Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A (1993) 5.02
ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet (2002) 3.38
Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension (2007) 2.77
Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res (2004) 2.52
Hypertensive disorders and severe obstetric morbidity in the United States. Obstet Gynecol (2009) 2.12
Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology (Bethesda) (2009) 2.10
An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol (2009) 1.92
Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of vascular endothelial growth factor receptor 1. J Biol Chem (2005) 1.90
Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation (2012) 1.88
Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia. Am J Obstet Gynecol (2005) 1.81
A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use. J Cell Mol Med (2009) 1.59
The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol (2011) 1.50
Risks of preeclampsia and adverse neonatal outcomes among women with pregestational diabetes mellitus. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Am J Obstet Gynecol (2000) 1.35
What we have learned about preeclampsia. Semin Perinatol (2003) 1.34
Global and regional estimates of preeclampsia and eclampsia: a systematic review. Eur J Obstet Gynecol Reprod Biol (2013) 1.33
Hypoxia and sFlt-1 in preeclampsia: the "chicken-and-egg" question. Endocrinology (2004) 1.33
Intronic polyadenylation signal sequences and alternate splicing generate human soluble Flt1 variants and regulate the abundance of soluble Flt1 in the placenta. FASEB J (2007) 1.22
Identification of ligand-induced proteolytic cleavage and ectodomain shedding of VEGFR-1/FLT1 in leukemic cancer cells. Cancer Res (2009) 1.22
Angiogenic factors for the prediction of preeclampsia in high-risk women. Am J Obstet Gynecol (2007) 1.20
Novel splice variants of sFlt1 are upregulated in preeclampsia. Placenta (2009) 1.14
Pre-eclampsia and cardiovascular disease. Cardiovasc Res (2014) 1.10
Novel soluble Flt-1 isoforms in plasma and cultured placental explants from normotensive pregnant and preeclamptic women. Placenta (2008) 1.07
Changes in pregnancy mortality ascertainment: United States, 1999-2005. Obstet Gynecol (2011) 1.05
Soluble VEGF receptor Flt1: the elusive preeclampsia factor discovered? J Clin Invest (2003) 1.04
Angiogenic growth factors in the diagnosis and prediction of pre-eclampsia. Clin Sci (Lond) (2012) 1.00
Angiogenic factors in preeclampsia and related disorders. Cold Spring Harb Perspect Med (2012) 0.99
Circulating angiogenic factors in singleton vs multiple-gestation pregnancies. Am J Obstet Gynecol (2008) 0.96
Gestational angiogenic biomarker patterns in high risk preeclampsia groups. Am J Obstet Gynecol (2013) 0.92
Diabetes and the kidney in pregnancy. Semin Nephrol (2011) 0.89
Placental expression of a novel primate-specific splice variant of sFlt-1 is upregulated in pregnancies complicated by severe early onset pre-eclampsia. BJOG (2011) 0.87
Expression of placental FLT1 transcript variants relates to both gestational hypertensive disease and fetal growth. Hypertension (2011) 0.87
Changes in circulating concentrations of soluble fms-like tyrosine kinase-1 and placental growth factor measured by automated electrochemiluminescence immunoassays methods are predictors of preeclampsia. J Hypertens (2012) 0.83
Pre-eclampsia. BMJ (2012) 0.80
Angiogenic biomarkers for prediction of early preeclampsia onset in high-risk women. J Matern Fetal Neonatal Med (2013) 0.80
The use of angiogenic factors in discriminating preeclampsia: are they ready for prime time? J Matern Fetal Neonatal Med (2010) 0.79
Variability in mRNA expression of fms-like tyrosine kinase-1 variants in normal and preeclamptic placenta. BMC Res Notes (2014) 0.76